Last Updated on October 15, 2024 by The Health Master
Lupin recently announced that it has received approval from the US Food and Drug Administration (USFDA) to market Doxycycline capsules used to treat bacterial infections in the US market, according to a statement from the company.
The drug firm has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated New Drug Application (ANDA) for Doxycycline capsules, 40 mg, a generic equivalent of Galderma Laboratories’ Oracea capsules, the statement added.
USFDA gives tentative approval for Drospirenone tablets
USFDA approves Ketorolac Tromethamine injection
USFDA gives final approval for Sodium Phenylbutyrate tablets
USFDA gives approval for Glycopyrrolate injection
USFDA gives final approval for Mesalamine extended-release capsules
USFDA gives final approval for Paclitaxel injection
USFDA issued OAI Status to Sun Pharma
Pharmacy Inspectors to be appointed soon
PCI clarifies its decision to restore admission intakes
Drug recall: These drugs recalled by Aurobindo for this reason
Lab-made Blood given to people in world-first Clinical Trial
USFDA gives tentative approval for Drospirenone tablets
IPC adds 10 new Impurity Reference Substances to IP 2022
USFDA issues warning letter to Lupin API plant
NPPA to consider Retail Price Fixation of this Asthma Drug Combination
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
